Previous reports showed that early treatment with IL-1 inhibitors Anakinra or Canakinumab in patients with NLRP3 mutations can improve hearing and prevent irreversible renal damage from amyloidosis [12, 14]. The gene discussed is NLRP3; the disease is amyloidosis.